- First patient for Phase 1/2 SUNRISE trial expected to be enrolled by mid-year 2021
- Business Development Deals signed with Daichi-Sankyo and CANbridge Pharmaceuticals
- New members recently added to Leadership Team
PR Newswire
LEXINGTON, Mass., May 10, 2021